Skip to Content

Cell/Gene Therapy & Tumor Immunology

Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Position Description:

We are seeking a highly devoted and enthusiastic PhD or MD/PhD scientist to join our group as a post-doctoral research fellow. We recently identified mechanisms of response and resistance to chimeric antigen receptor (CAR) T cell therapy in leukemias 1. Our laboratory focuses on the functional fate mapping of CAR T cells using high-end single cell transcriptomics and proteomics approaches, combined with functional in vitro and in vivo mechanistic studies to further understand the long-term persistent memory CAR T cells and translate such findings into novel gene therapies for cancer.

We have a post-doctoral position open to support these efforts. This position will utilize next-generation single cell technologies to characterize and monitor chimeric antigen receptor (CAR) T cells from leukemia patients treated at our center with autologous CD19 CAR-redirected T cells. In addition, this position will study the biology of the CAR integration on the local, regional, and global gene activity in the modified T cells via gene editing technologies and deep mechanistic studies.


Preferred: Experience in tumor immunology and immunotherapy, mass cytometry, flow cytometric purification of cell populations using the BD Aria, substantial expertise with human/murine T cell functional assays (especially high definition polychromatic flow cytometry), gene editing via CRISPR/Cas9, and tumor mouse models, scientific knowledge and research experience in human immunology with a track record of publication in peer-reviewed journals.

Basic: Ph.D. and/or M.D. in immunology or genetics. Must have research experience in the cellular and molecular aspects of tumor immunology. Able to work well in a highly dynamic, collaborative work environment.

To Apply:

Please forward a cover letter describing your career plans, updated CV with research statement and the names/contact information for 3 professional references to:

J. Joseph Melenhorst, PhD
Department of Pathology and Laboratory Medicine
Center for Cellular Immunotherapies
Perelman School of Medicine
University of Pennsylvania


  1. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571. doi:10.1038/s41591-018-0010-1
  2. Fraietta JA, Nobles CL, Sammons MA, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. May 2018:1. doi:10.1038/s41586-018-0178-z
  3. Maus M V. Tumour tamed by transfer of one T cell. Nature. May 2018. doi:10.1038/d41586-018-05251-5